Inovelon

Rufinamide, the active ingredient in Inovelon, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of seizures associated with Lennox‑Gastaut syndrome in patients requiring adjunct therapy. GNH USA supplies Inovelon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rufinamide is an anticonvulsant used primarily in the management of refractory seizure disorders. - Lennox‑Gastaut syndrome: reduces the frequency of drop seizures and improves overall seizure control.

Rufinamide may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Dizziness: transient light‑headedness often occurring at treatment initiation. - Fatigue: persistent tiredness that may affect daily activities. - Nausea: mild to moderate stomach upset. - Headache: occasional throbbing pain.

Serious or Rare Side Effects: - Rash or severe skin reactions: may indicate hypersensitivity. - Suicidal thoughts: emergent mood changes requiring immediate evaluation. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Blood dyscrasias: rare reductions in blood cell counts. - QT prolongation: potential cardiac rhythm disturbance.

Before initiating therapy, clinicians should consider several safety aspects. - Renal impairment: adjust dose based on renal function. - Hepatic monitoring: check liver enzymes periodically. - Psychiatric history: use caution in patients with depression or suicidal ideation. - Discontinuation: avoid abrupt cessation to prevent seizure rebound. - Pregnancy and breastfeeding: consult specialist before use. - Store at room temperature: keep in the original pack, protect from moisture.

Rufinamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may lower rufinamide plasma concentrations. - Enzyme‑inducing antiepileptics (phenytoin, phenobarbital): can reduce therapeutic effect. - Strong CYP3A4 inhibitors (ketoconazole, erythromycin): may increase rufinamide exposure.

Moderate Interactions (Monitor Closely): - Oral contraceptives: potential reduction in contraceptive effectiveness. - Alcohol: may enhance central nervous system depression. - Other antiepileptics (valproate): monitor plasma levels for additive effects.